Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.

Amaudrut J, Argiriadi MA, Barth M, Breinlinger EC, Bressac D, Broqua P, Calderwood DJ, Chatar M, Cusack KP, Gauld SB, Jacquet S, Kamath RV, Kort ME, Lepais V, Luccarini JM, Masson P, Montalbetti C, Mounier L, Potin D, Poupardin O, Rouaud S, Spitzer L, Wallace CD.

Bioorg Med Chem Lett. 2019 Jul 15;29(14):1799-1806. doi: 10.1016/j.bmcl.2019.05.015. Epub 2019 May 9.

PMID:
31101472
2.

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Boubia B, Poupardin O, Barth M, Binet J, Peralba P, Mounier L, Jacquier E, Gauthier E, Lepais V, Chatar M, Ferry S, Thourigny A, Guillier F, Llacer J, Amaudrut J, Dodey P, Lacombe O, Masson P, Montalbetti C, Wettstein G, Luccarini JM, Legendre C, Junien JL, Broqua P.

J Med Chem. 2018 Mar 22;61(6):2246-2265. doi: 10.1021/acs.jmedchem.7b01285. Epub 2018 Feb 27.

PMID:
29446942
3.

The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.

Wettstein G, Luccarini JM, Poekes L, Faye P, Kupkowski F, Adarbes V, Defrêne E, Estivalet C, Gawronski X, Jantzen I, Philippot A, Tessier J, Tuyaa-Boustugue P, Oakley F, Mann DA, Leclercq I, Francque S, Konstantinova I, Broqua P, Junien JL.

Hepatol Commun. 2017 Jun 19;1(6):524-537. doi: 10.1002/hep4.1057. eCollection 2017 Aug.

4.

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.

Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, Cauvet A, Tu L, Luccarini JM, Junien JL, Broqua P, Allanore Y.

Ann Rheum Dis. 2017 Nov;76(11):1931-1940. doi: 10.1136/annrheumdis-2016-210821. Epub 2017 Aug 11.

PMID:
28801346
5.

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.

Ruzehaji N, Frantz C, Ponsoye M, Avouac J, Pezet S, Guilbert T, Luccarini JM, Broqua P, Junien JL, Allanore Y.

Ann Rheum Dis. 2016 Dec;75(12):2175-2183. doi: 10.1136/annrheumdis-2015-208029. Epub 2016 Mar 9.

6.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.

Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL.

J Pharmacol Exp Ther. 2010 Jan;332(1):190-201. doi: 10.1124/jpet.109.157388. Epub 2009 Oct 14.

PMID:
19828876
7.

Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.

Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C.

J Pharmacol Exp Ther. 2007 Mar;320(3):1113-8. Epub 2006 Dec 19.

PMID:
17179469
8.

Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance.

Schwach G, Oudry N, Giliberto JP, Broqua P, Lück M, Lindner H, Gurny R.

Eur J Pharm Biopharm. 2004 May;57(3):441-6.

PMID:
15093591
9.

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.

Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML.

Diabetes. 2002 May;51(5):1461-9.

10.

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.

Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL.

J Pharmacol Exp Ther. 2002 Apr;301(1):95-102.

PMID:
11907162
11.
12.

Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach.

de Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Gonçalves R, Dutrillaux AM, Némati F, Oudard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF.

Am J Pathol. 2001 Aug;159(2):753-64.

13.

GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.

Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, Rivier JE.

J Med Chem. 2001 Feb 1;44(3):453-67.

PMID:
11462984
14.
15.

Stimulation of the gonadotropic axis by the neuropeptide Y receptor Y1 antagonist/Y4 agonist 1229U91 in the male rat.

Raposinho PD, Broqua P, Hayward A, Akinsanya K, Galyean R, Schteingart C, Junien J, Aubert ML.

Neuroendocrinology. 2000 Jan;71(1):2-7.

PMID:
10644893
16.

Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.

Raposinho PD, Broqua P, Pierroz DD, Hayward A, Dumont Y, Quirion R, Junien JL, Aubert ML.

Endocrinology. 1999 Sep;140(9):4046-55.

PMID:
10465275
17.

The discriminative stimulus properties of U50,488 and morphine are not shared by fedotozine.

Broqua P, Wettstein JG, Rocher MN, Rivière PJ, Dahl SG.

Eur Neuropsychopharmacol. 1998 Dec;8(4):261-6.

PMID:
9928914
18.

Antinociceptive effects of neuropeptide Y and related peptides in mice.

Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Riviere PJ, Junien JL, Dahl SG.

Brain Res. 1996 Jun 10;724(1):25-32.

PMID:
8816252
19.

Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures.

Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL.

Behav Pharmacol. 1995 Apr;6(3):215-222.

PMID:
11224329
20.

Antidepressant/anxiolytic ipsapirone inhibits cold-induced hypothalamic TRH release.

Broqua P, Benyassi A, Grouselle D, Arancibia S.

Neuroreport. 1993 Sep 3;4(10):1200-2.

PMID:
8106004
21.

Are 5-HT1A autoreceptors involved in the inhibitory effect of ipsapirone on cold-elicited thyrotropin secretion?

Broqua P, Laude D, Bluet-Pajot MT, Schmidt B, Baudrie V, Chaouloff F.

Neuroendocrinology. 1993 Apr;57(4):640-7.

PMID:
7690117
22.

Subchronic treatment with anxiolytic doses of the 5-HT1A receptor agonist ipsapirone does not affect 5-HT2 receptor sensitivity in the rat.

Baudrie V, De Vry J, Broqua P, Schmidt B, Chaouloff F, Glaser T.

Eur J Pharmacol. 1993 Feb 16;231(3):395-406.

PMID:
8095465
23.

Effects of cold stress on some 5-HT1A, 5-HT1C and 5-HT2 receptor-mediated responses.

Zamfir O, Broqua P, Baudrie V, Chaouloff F.

Eur J Pharmacol. 1992 Aug 25;219(2):261-9.

PMID:
1385172
24.
25.

The 5-HT2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane increases brain tryptophan levels in the rat.

Chaouloff F, Baudrie V, Layeillon C, Broqua P.

Eur J Pharmacol. 1992 Apr 7;214(1):101-3.

PMID:
1533838
26.

Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats.

Broqua P, Baudrie V, Laude D, Chaouloff F.

Biol Psychiatry. 1992 Feb 15;31(4):391-400.

PMID:
1558901
27.

Buspirone, ipsapirone and 1-(2-pyrimidinyl)-piperazine decrease cold-induced thyrotropin secretion in rats.

Broqua P, Baudrie V, Bluet-Pajot MT, Chaouloff F.

Eur J Pharmacol. 1991 Nov 5;204(2):141-7.

PMID:
1687218
28.

In vivo evidence that insulin does not inhibit hepatic tryptophan pyrrolase activity in rats.

Broqua P, Baudrie V, Laude D, Guezennec Y, Chaouloff F.

Biochem Pharmacol. 1990 Aug 15;40(4):759-63.

PMID:
2201300

Supplemental Content

Loading ...
Support Center